Cystic fibrosis care with highly effective modulators
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how cystic fibrosis care is organized when patients take highly effective CFTR modulator drugs. It aims to understand if care needs change for those on modulators compared to those who cannot take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis and are 6 years or older
- You have been taking a highly effective CFTR modulator for at least 12 months, or you are not eligible for this treatment
- If you are under 18, your family can also take part
- You are a healthcare professional (doctor, nurse, physiotherapist) who has worked in a cystic fibrosis center for more than 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This study looks at how highly effective CF modulator therapies change the bacteria living in the lungs of people with cystic fibrosis. Understanding these changes may help improve future treatments.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.